EP0956013B1
(en)
*
|
1996-10-11 |
2003-04-09 |
Scarista Limited |
Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
|
ES2257824T3
(es)
*
|
1998-01-28 |
2006-08-01 |
Warner-Lambert Company Llc |
Metodo para tratar la enfermedad de alzheimer.
|
US6107334A
(en)
|
1998-02-23 |
2000-08-22 |
Wake Forest University |
Dietary control of arachidonic acid metabolism
|
US7138431B1
(en)
|
1998-02-23 |
2006-11-21 |
Wake Forest University |
Dietary control of arachidonic acid metabolism
|
FR2788437B1
(fr)
*
|
1999-01-14 |
2006-08-11 |
Inst Rech Biolog Sa |
Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
|
AU2006201772B2
(en)
*
|
1999-01-27 |
2010-02-04 |
Amarin Neuroscience Limited |
Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
|
GB9901808D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Drugs for treatment of psychiatric and brain disorders
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
GB9904895D0
(en)
*
|
1999-03-03 |
1999-04-28 |
Scarista Limited |
Regulators of coenzyme-A-independent transacylase as psychotropic drugs
|
ES2425114T3
(es)
*
|
2000-03-16 |
2013-10-11 |
The Mclean Hospital Corporation |
CDP-colina y uridina para el tratamiento del abuso del acohol
|
IL142535A0
(en)
*
|
2001-04-11 |
2002-03-10 |
Yeda Res & Dev |
Pharmaceutical compositions for the treatment of inflammation
|
IL142536A0
(en)
*
|
2001-04-11 |
2002-03-10 |
Yeda Res & Dev |
Carriers for therapeutic preparations for treatment of t-cell mediated diseases
|
WO2002092779A2
(en)
*
|
2001-05-17 |
2002-11-21 |
Pilot Therapeutics, Inc. |
Method for enriching tissues in long chain polyunsaturated fatty acids
|
EP1842567A3
(en)
|
2001-11-08 |
2008-01-02 |
Atrium Medical Corporation |
Intraluminal device with a coating containing a therapeutic agent
|
NL1019368C2
(nl)
|
2001-11-14 |
2003-05-20 |
Nutricia Nv |
Preparaat voor het verbeteren van receptorwerking.
|
NZ539106A
(en)
*
|
2002-10-10 |
2007-02-23 |
Yeda Res & Dev |
Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
|
GB0311081D0
(en)
|
2003-05-14 |
2003-06-18 |
Btg Internat Limted |
Treatment of neurodegenerative conditions
|
EP1660071A1
(en)
*
|
2003-08-18 |
2006-05-31 |
Btg International Limited |
Treatment of neurodegenerative conditions
|
CA2542023A1
(en)
*
|
2003-10-08 |
2005-09-22 |
The Mclean Hospital Corporation |
Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
|
US20050113449A1
(en)
*
|
2003-10-08 |
2005-05-26 |
Renshaw Perry F. |
Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
|
WO2005072306A2
(en)
*
|
2004-01-19 |
2005-08-11 |
Martek Biosciences Corporation |
Reelin deficiency or dysfunction and methods related thereto
|
ITMI20040069A1
(it)
*
|
2004-01-21 |
2004-04-21 |
Tiberio Bruzzese |
Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
|
US7022713B2
(en)
*
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
US20050266051A1
(en)
*
|
2004-05-27 |
2005-12-01 |
The Procter & Gamble Company |
Pet food compositions and methods
|
US20090215714A1
(en)
*
|
2004-06-10 |
2009-08-27 |
Perry Renshaw |
Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
|
EP1765075A4
(en)
*
|
2004-06-10 |
2010-11-10 |
Mclean Hospital Corp |
PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS
|
WO2006020703A1
(en)
*
|
2004-08-11 |
2006-02-23 |
The Mclean Hospital Corporation |
Compounds for the treatment of marihuana dependence, withdrawal, and usage
|
US8312836B2
(en)
|
2004-09-28 |
2012-11-20 |
Atrium Medical Corporation |
Method and apparatus for application of a fresh coating on a medical device
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
WO2006036983A2
(en)
|
2004-09-28 |
2006-04-06 |
Atrium Medical Corporation |
Pre-dried drug delivery coating for use with a stent
|
US9801982B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Implantable barrier device
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US8367099B2
(en)
|
2004-09-28 |
2013-02-05 |
Atrium Medical Corporation |
Perforated fatty acid films
|
US20090011116A1
(en)
*
|
2004-09-28 |
2009-01-08 |
Atrium Medical Corporation |
Reducing template with coating receptacle containing a medical device to be coated
|
US20060083768A1
(en)
*
|
2004-09-28 |
2006-04-20 |
Atrium Medical Corporation |
Method of thickening a coating using a drug
|
US8124127B2
(en)
|
2005-10-15 |
2012-02-28 |
Atrium Medical Corporation |
Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
|
US20060067976A1
(en)
|
2004-09-28 |
2006-03-30 |
Atrium Medical Corporation |
Formation of barrier layer
|
US7550286B2
(en)
|
2004-11-04 |
2009-06-23 |
E. I. Du Pont De Nemours And Company |
Docosahexaenoic acid producing strains of Yarrowia lipolytica
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
JP2008520739A
(ja)
*
|
2004-11-19 |
2008-06-19 |
マーテック・バイオサイエンシーズ・コーポレーション |
長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
GB0425932D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Btg Int Ltd |
Structured phospholipids
|
GB2421909A
(en)
*
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
GB0504333D0
(en)
*
|
2005-03-02 |
2005-04-06 |
Btg Int Ltd |
Treatment of cytokine dysregulation
|
GB0504362D0
(en)
|
2005-03-02 |
2005-04-06 |
Btg Int Ltd |
Cytokine modulators
|
KR20180026556A
(ko)
*
|
2005-07-08 |
2018-03-12 |
디에스엠 아이피 어셋츠 비.브이. |
치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US9278161B2
(en)
|
2005-09-28 |
2016-03-08 |
Atrium Medical Corporation |
Tissue-separating fatty acid adhesion barrier
|
NZ569068A
(en)
*
|
2005-12-20 |
2011-11-25 |
Cenestra Llc |
Omega 3 fatty acid formulations of EPA and DHA
|
WO2007090162A2
(en)
*
|
2006-01-31 |
2007-08-09 |
Martek Biosciences Corporation |
OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
|
EP2083875B1
(en)
|
2006-11-06 |
2013-03-27 |
Atrium Medical Corporation |
Coated surgical mesh
|
US9492596B2
(en)
|
2006-11-06 |
2016-11-15 |
Atrium Medical Corporation |
Barrier layer with underlying medical device and one or more reinforcing support structures
|
US20100130611A1
(en)
*
|
2006-12-20 |
2010-05-27 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
EP2120920A4
(en)
*
|
2007-02-20 |
2011-06-15 |
Martek Biosciences Corp |
OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
|
WO2008106091A1
(en)
*
|
2007-02-26 |
2008-09-04 |
Yeda Research And Development Co. Ltd. |
Use of long-chain alcohol derivatives for the treatment of alopecia areata
|
EP2114155A4
(en)
*
|
2007-02-26 |
2014-04-16 |
Yeda Res & Dev |
AMINO-PHENYL-ACETIC ACID OCTADEC-9- (Z) ENANTIOMERS, THEIR SALTS AND USES THEREOF
|
EP2195415A1
(en)
|
2007-10-03 |
2010-06-16 |
E. I. du Pont de Nemours and Company |
Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
|
WO2009058799A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Wake Forest University School Of Medicine |
Compositions and methods for prevention and treatment of mammalian diseases
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
US20110027841A1
(en)
*
|
2007-12-21 |
2011-02-03 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
US20100041621A1
(en)
*
|
2008-08-15 |
2010-02-18 |
Perry Renshaw |
Methods and compositions for improving cognitive performance
|
EP3187182B1
(en)
|
2008-09-02 |
2021-03-03 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
AU2015203289B2
(en)
*
|
2008-09-09 |
2017-03-16 |
Orygen Research Centre |
Prevention of psychotic disorders and/or treatment of psychotic symptoms
|
AU2008361645A1
(en)
*
|
2008-09-09 |
2010-03-18 |
Orygen Research Centre |
Prevention of psychotic disorders and/or treatment of psychotic symptoms
|
US8060617B2
(en)
*
|
2008-12-19 |
2011-11-15 |
Cisco Technology, Inc. |
Reserving network resources during scheduling of meeting event
|
CA3089847C
(en)
|
2009-02-10 |
2024-04-09 |
Amarin Pharmaceuticals Ireland Limited |
Use of eicosapentaenoic acid to treat hypertriglyceridemia
|
GB0904300D0
(en)
|
2009-03-12 |
2009-04-22 |
Amarin Neuroscience Ltd |
Essential fatty acid compounds
|
CN106822080A
(zh)
|
2009-04-29 |
2017-06-13 |
阿马里纳药物爱尔兰有限公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
PL2424356T3
(pl)
|
2009-04-29 |
2018-03-30 |
Amarin Pharmaceuticals Ireland Limited |
Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
|
CN106074486A
(zh)
|
2009-06-15 |
2016-11-09 |
阿马里纳药物爱尔兰有限公司 |
在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
SG10201405994UA
(en)
|
2009-09-23 |
2014-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
|
US8372465B2
(en)
|
2010-02-17 |
2013-02-12 |
Bunge Oils, Inc. |
Oil compositions of stearidonic acid
|
SG183883A1
(en)
*
|
2010-03-04 |
2012-10-30 |
Amarin Pharma Inc |
Compositions and methods for treating and/or preventing cardiovascular disease
|
EP2593141B1
(en)
|
2010-07-16 |
2018-07-04 |
Atrium Medical Corporation |
Composition and methods for altering the rate of hydrolysis of cured oil-based materials
|
NZ744990A
(en)
|
2010-11-29 |
2019-10-25 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
WO2012083034A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Louis Sanfilippo |
Modulation of neurotrophic factors by omega-3 fatty acid formulations
|
US8952000B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
|
US9119826B2
(en)
|
2011-02-16 |
2015-09-01 |
Pivotal Therapeutics, Inc. |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
|
US8715648B2
(en)
|
2011-02-16 |
2014-05-06 |
Pivotal Therapeutics Inc. |
Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
|
US8951514B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
|
EP2540292A1
(en)
*
|
2011-06-28 |
2013-01-02 |
Nestec S.A. |
DHA and EPA in the reduction of oxidative stress
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
JP6307442B2
(ja)
|
2012-01-06 |
2018-04-04 |
アマリン ファーマシューティカルス アイルランド リミテッド |
対象の高感度(hs−crp)のレベルを低下させる組成物および方法
|
US9867880B2
(en)
|
2012-06-13 |
2018-01-16 |
Atrium Medical Corporation |
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
|
MX2020008890A
(es)
|
2012-06-29 |
2022-08-15 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
KR20160137528A
(ko)
*
|
2014-02-07 |
2016-11-30 |
유니버시티 오브 유타 리서치 파운데이션 |
크레아틴, 오메가-3 지방산 및 시티콜린의 조합
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
WO2016063959A1
(ja)
*
|
2014-10-24 |
2016-04-28 |
日油株式会社 |
環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
|
ES2607715B1
(es)
*
|
2015-10-01 |
2018-01-17 |
Solutex Na, Lcc |
Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
TW201900160A
(zh)
|
2017-05-19 |
2019-01-01 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
MA50490A
(fr)
|
2018-09-24 |
2020-09-02 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|
US11986452B2
(en)
|
2021-04-21 |
2024-05-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|